Hyperthermia intravesical chemotherapy acts as a promising alternative to bacillus Calmette-Guérin instillation in non-muscle-invasive bladder cancer: a network meta-analysis

• Published in: Frontiers in oncology 2023, Vol.13, p.1164932-1164932
• Main Authors: Zeng, Na, Xu, Meng-Yao, Sun, Jian-Xuan, Liu, Chen-Qian, Xu, Jin-Zhou, An, Ye, Zhong, Xing-Yu, Ma, Si-Yang, He, Hao-Dong, Xia, Qi-Dong, Wang, Shao-Gang
• Format: Article
• Language: English
• Subjects: adjuvant therapy; BCG; HIVEC; hyperthermia intravesical chemotherapy; network meta-analysis; non-muscle-invasive bladder cancer; Oncology
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2023.1164932

With the shortage of bacillus Calmette-Guérin (BCG) vaccine, it is important to find an alternative to BCG instillation, which is the most commonly used adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC) patients after transurethral resection of bladder tumor treatment (TURBt) to delay tumor recurrence. Hyperthermia intravesical chemotherapy (HIVEC) with mitomycin C (MMC) is a potential treatment choice. We aim to compare HIVEC with BCG instillation for the preventive efficacy of bladder tumor recurrence and progression. A network meta-analysis (NMA) was taken with MMC instillation and TURBt as the attached comparators. Randomized controlled trials (RCTs) with NIMBC patients after TURBt were included. Articles with pure BCG unresponsive patients and combined therapies were excluded. The study protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO, CRD42023390363). It was found that HIVEC had a non-significant 22% relative reduction in bladder tumor recurrence compared with BCG instillation [HIVEC vs. BCG: HR 0.78, 95% credible interval (CrI) 0.55-1.08] and a nonsignificant higher risk of bladder tumor progression (BCG vs. HIVEC: HR 0.77, 95% CrI 0.22-3.03). HIVEC is a potential alternative to BCG, and it is expected to be the standard therapy for NMIBC patients after TURBt during the global shortage of BCG. PROSPERO identifier, CRD42023390363.